Progress in cystic fibrosis and the CF Therapeutics Development Network

Cystic fibrosis (CF), the most common life-shortening genetic disorder in Caucasians, affects approximately 70 000 individuals worldwide. In 1998, the Cystic Fibrosis Foundation (CFF) launched the CF Therapeutics Development Network (CF-TDN) as a central element of its Therapeutics Development Programme. Designed to accelerate the clinical evaluation of new therapies needed to fulfil the CFF mission to control and cure CF, the CF-TDN has conducted 75 clinical trials since its inception, and has contributed to studies as varied as initial safety and proof of concept trials to pivotal programmes required for regulatory approval. This review highlights recent and significant research efforts of the CF-TDN, including a summary of contributions to studies involving CF transmembrane conductance regulator (CFTR) modulators, airway surface liquid hydrators and mucus modifiers, anti-infectives, anti-inflammatories, and nutritional therapies. Efforts to advance CF biomarkers, necessary to accelerate the therapeutic goals of the network, are also summarised.

[1]  J. Emerson,et al.  Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.

[2]  M. Wilschanski,et al.  Liprotamase Long-term Safety and Support of Nutritional Status in Pancreatic-insufficient Cystic Fibrosis , 2012, Journal of pediatric gastroenterology and nutrition.

[3]  J. Kaiser.  Personalized medicine. New cystic fibrosis drug offers hope, at a price. , 2012, Science.

[4]  M. Knowles,et al.  Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. , 1981, The New England journal of medicine.

[5]  J. Emerson,et al.  Baseline Characteristics and Factors Associated With Nutritional and Pulmonary Status at Enrollment in the Cystic Fibrosis EPIC Observational Cohort , 2010, Pediatric pulmonology.

[6]  R. Gibson,et al.  No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. , 2007, American journal of respiratory cell and molecular biology.

[7]  J. Clancy,et al.  Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. , 2004, Chest.

[8]  R. Gibson,et al.  Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. , 2009, Chest.

[9]  Mark R Elkins,et al.  A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. , 2006, The New England journal of medicine.

[10]  Richard C. Boucher,et al.  Regulation of Murine Airway Surface Liquid Volume by CFTR and Ca2+-activated Cl− Conductances , 2002, The Journal of general physiology.

[11]  N. McCarty,et al.  Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis * * , 2002, Pediatric pulmonology.

[12]  P. Flume,et al.  Update in cystic fibrosis 2010. , 2011, American journal of respiratory and critical care medicine.

[13]  C. Goss,et al.  A story of success: continuous quality improvement in cystic fibrosis care in the USA , 2011, Thorax.

[14]  R. Wenzel,et al.  Antibiotic prevention of acute exacerbations of COPD. , 2012, The New England journal of medicine.

[15]  C. Goss,et al.  Safety and Preliminary Clinical Activity of a Novel Pancreatic Enzyme Preparation in Pancreatic Insufficient Cystic Fibrosis Patients , 2006, Pancreas.

[16]  R. Gibson,et al.  Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. , 2008, American journal of respiratory and critical care medicine.

[17]  S. Sagel,et al.  Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[18]  C. Penland,et al.  Cystic fibrosis foundation: achieving the mission. , 2009, Respiratory care.

[19]  S. Peltz,et al.  WS7.5 Interim results of the phase 3 open-label study of ataluren in nonsense mutation cystic fibrosis (nmCF) , 2013 .

[20]  G. Graff,et al.  Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study. , 2010, Clinical therapeutics.

[21]  J. Clancy,et al.  Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line , 1997, Nature Medicine.

[22]  M. Campion,et al.  International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[23]  L. Shamseer,et al.  Antioxidant micronutrients for lung disease in cystic fibrosis. , 2010, The Cochrane database of systematic reviews.

[24]  J. Stockman.  Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosa: A Randomized Controlled Trial , 2012 .

[25]  T. Liou,et al.  Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. , 2012, Chest.

[26]  S. Peltz,et al.  PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model , 2008, Proceedings of the National Academy of Sciences.

[27]  R. Boucher,et al.  Transcellular sodium transport in cultured cystic fibrosis human nasal epithelium. , 1991, The American journal of physiology.

[28]  S. Caras,et al.  Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[29]  M. Rieder,et al.  Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis , 2012, Nature Genetics.

[30]  D. Geddes,et al.  No added benefit from nebulized amiloride in patients with cystic fibrosis. , 1993, The European respiratory journal.

[31]  Richard C Boucher,et al.  Normal and Cystic Fibrosis Airway Surface Liquid Homeostasis , 2005, Journal of Biological Chemistry.

[32]  M. Konstan,et al.  The role of inflammation in the pathophysiology of CF lung disease , 2002, Clinical reviews in allergy & immunology.

[33]  D. Solís.  US Food and Drug Administration , 2010 .

[34]  M. Konstan,et al.  Sputum biomarkers of inflammation in cystic fibrosis lung disease. , 2007, Proceedings of the American Thoracic Society.

[35]  F. Vermeulen,et al.  Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. , 2010, American journal of respiratory and critical care medicine.

[36]  K. Hardy,et al.  EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[37]  R. Gibson,et al.  Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.

[38]  S. Willsie.  Inhaled Aztreonam Lysine For Chronic Airway Pseudomonas aeruginosa In Cystic Fibrosis , 2010 .

[39]  Todd A. Durham,et al.  Long term effects of denufosol tetrasodium in patients with cystic fibrosis. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[40]  R. Kronmal,et al.  Advancing outcome measures for the new era of drug development in cystic fibrosis. , 2007, Proceedings of the American Thoracic Society.

[41]  Meenal Patel,et al.  PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.

[42]  M. Rosenfeld,et al.  Endpoints for clinical trials in young children with cystic fibrosis. , 2007, Proceedings of the American Thoracic Society.

[43]  B. Trapnell,et al.  Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[44]  R. Boucher,et al.  Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium , 1991, British journal of pharmacology.

[45]  G. Bellon,et al.  Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. , 2012, American journal of respiratory and critical care medicine.

[46]  H. Forman,et al.  Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003. , 2007, Free radical biology & medicine.

[47]  L. Duffy,et al.  Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. , 2004, The Journal of pediatrics.

[48]  J. Rousset,et al.  In vitro prediction of stop-codon suppression by intravenous gentamicin patients with cystic fibrosis : a pilot study , 2022 .

[49]  R. Gibson,et al.  Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalating Study of Aerosolized Interferon Gamma‐1b in Patients With Mild to Moderate Cystic Fibrosis Lung Disease , 2005, Pediatric pulmonology.

[50]  J. Clancy,et al.  Personalized medicine in cystic fibrosis: dawning of a new era. , 2012, American journal of respiratory and critical care medicine.

[51]  L. Saiman,et al.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. , 2003, JAMA.

[52]  Umer Khan,et al.  Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. , 2011, Archives of pediatrics & adolescent medicine.

[53]  J. Lloyd-Still,et al.  High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. , 1997, The New England journal of medicine.

[54]  R. Gibson,et al.  Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: Results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis , 2005, Pediatric pulmonology.

[55]  B. Yankaskas,et al.  Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. , 2007, American journal of respiratory and critical care medicine.

[56]  A. Quittner,et al.  Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. , 2009, Chest.

[57]  L. Saiman,et al.  Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. , 2012, Chest.

[58]  M. Konstan,et al.  Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial , 2011, Pediatric pulmonology.

[59]  R. Kronmal,et al.  Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting. , 2005, Contemporary clinical trials.

[60]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[61]  R. Kronmal,et al.  Association between pulmonary function and sputum biomarkers in cystic fibrosis. , 2007, American journal of respiratory and critical care medicine.

[62]  Todd A. Durham,et al.  Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. , 2011, American journal of respiratory and critical care medicine.

[63]  H. Quinton,et al.  Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. , 2008, Journal of the American Dietetic Association.

[64]  R. Gibson,et al.  An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis , 2010, Pediatric pulmonology.

[65]  C. Goss,et al.  The Cystic Fibrosis Foundation Therapeutics Development Network: A National Effort by the Cystic Fibrosis Foundation to Build a Clinical Trials Network , 2008 .

[66]  M R Kosorok,et al.  Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. , 2000, The New England journal of medicine.

[67]  B. Kerem,et al.  Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. , 2003, The New England journal of medicine.

[68]  D. Schidlow,et al.  A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. , 1995, The Journal of pediatrics.

[69]  J. Emerson,et al.  Standardized procedure for measurement of nasal potential difference: An outcome measure in multicenter cystic fibrosis clinical trials , 2004, Pediatric pulmonology.

[70]  R. Gibson,et al.  Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis , 2007, Pediatric pulmonology.

[71]  J. Clancy,et al.  Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.

[72]  J. Emerson,et al.  Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis , 2007, Pediatric pulmonology.

[73]  M. Berger,et al.  Chronic Inflammation in the Cystic Fibrosis Lung: Alterations in Inter- and Intracellular Signaling , 2008, Clinical reviews in allergy & immunology.

[74]  E. Block.  A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis , 2006 .

[75]  Jinglan Zhou,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[76]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[77]  H. Fuchs,et al.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. , 1994, The New England journal of medicine.

[78]  M. Sockrider,et al.  The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. , 1999, Chest.

[79]  R. Kronmal,et al.  Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis , 2012, Pediatric pulmonology.

[80]  M. King,et al.  A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. , 1990, The New England journal of medicine.

[81]  M. Knowles,et al.  Mucus clearance and lung function in cystic fibrosis with hypertonic saline. , 2006, The New England journal of medicine.

[82]  Eitan Kerem,et al.  Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial , 2008, The Lancet.

[83]  T. Ferkol,et al.  Airway inflammation in cystic fibrosis. , 2008, Chest.

[84]  M. Ballmann,et al.  WS5.1 Inhaled glutathione in cystic fibrosis , 2012 .

[85]  L. LaVange,et al.  Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. , 2007, American journal of respiratory and critical care medicine.

[86]  C. Goss,et al.  Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. , 2006, The Journal of pediatrics.

[87]  P. J. Byard,et al.  Effect of high-dose ibuprofen in patients with cystic fibrosis. , 1995, The New England journal of medicine.

[88]  J C Olsen,et al.  CFTR as a cAMP-dependent regulator of sodium channels , 1995, Science.

[89]  L. Wood,et al.  Oxidative Stress in Cystic Fibrosis: Dietary and Metabolic Factors , 2001, Journal of the American College of Nutrition.

[90]  J. Clancy,et al.  Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. , 2001, American journal of respiratory and critical care medicine.

[91]  M. Corey,et al.  High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. , 2007, The Journal of pediatrics.

[92]  S. Rowe,et al.  Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis , 2010, Current opinion in pulmonary medicine.

[93]  S. Kazerounian,et al.  Generic and alternative brand-name pharmaceutical equivalents: select with caution. , 1993, American journal of hospital pharmacy.

[94]  T. Dolan.  Update: cystic fibrosis. , 1986, Pediatric annals.

[95]  A. Mebazaa,et al.  Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized,double-blind, placebo-controlled trial* , 2012, Critical care medicine.

[96]  R. Kronmal,et al.  The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases. , 2002, Advanced drug delivery reviews.

[97]  R. Kronmal,et al.  Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. , 2012, JAMA.

[98]  C. Metcalfe,et al.  Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial , 2009, Thorax.

[99]  W. Morgan,et al.  Trends in the use of routine therapies in cystic fibrosis: 1995–2005 , 2010, Pediatric pulmonology.

[100]  W. Guggino,et al.  A phase I trial of intranasal Moli1901 for cystic fibrosis. , 2004, Chest.

[101]  M. Konstan,et al.  Anti-Inflammatory Medications for Cystic Fibrosis Lung Disease , 2005, Treatments in respiratory medicine.

[102]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[103]  J. Clancy,et al.  An international randomized multicenter comparison of nasal potential difference techniques. , 2010, Chest.

[104]  A. Brody.  Computed tomography scanning in cystic fibrosis research trials: practical lessons from three clinical trials in the United States. , 2007, Proceedings of the American Thoracic Society.

[105]  Fei Wang,et al.  Deletion of phenylalanine 508 causes attenuated phosphorylation‐dependent activation of CFTR chloride channels , 2000, The Journal of physiology.

[106]  J. Clancy,et al.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation , 2011, Thorax.

[107]  S. Randell,et al.  Evidence for Periciliary Liquid Layer Depletion, Not Abnormal Ion Composition, in the Pathogenesis of Cystic Fibrosis Airways Disease , 1998, Cell.

[108]  R. Fischer,et al.  Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. , 2011, American journal of respiratory and critical care medicine.

[109]  M. Rosenfeld,et al.  Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints. , 2010, American journal of respiratory and critical care medicine.

[110]  M. King,et al.  Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. , 1990, The American review of respiratory disease.

[111]  M. Knowles,et al.  A multicenter study of the effect of solution temperature on nasal potential difference measurements. , 2003, Chest.

[112]  C. Gallagher,et al.  Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study , 2011, European Respiratory Journal.